Casku 3D comprime tratamiento craneal infantil de 8 a 3 meses con impresión 3D

A child born with a misshapen skull used to face a long wait. Eight months of treatment, typically, with plaster molds and hand-fitted braces that required repeated trips to a specialist in the capital. For families in Chile's regions—La Serena, Viña del Mar, Concepción, Puerto Montt—that meant travel, time away from work, and often the choice to forgo treatment altogether. Casku 3D, a Chilean startup founded in July 2024, has compressed that timeline to between two and five months using 3D scanning and printing technology, and in doing so has begun to dismantle one of healthcare's quietest barriers: geography.

About one in five infants develops some form of positional cranial deformity—a flattening or asymmetry of the skull caused by prolonged pressure during sleep or positioning. Most cases resolve on their own. But moderate to severe cases require intervention with a custom orthosis, a brace that gently reshapes the skull as the child grows. The traditional method is labor-intensive: a clinician takes a plaster mold, a technician hand-fabricates the brace, and the patient returns for manual adjustments based on visual assessment. It works, but it is slow and geographically concentrated in urban centers.

Casku's founders—Patricio Martínez, a pediatric osteopath; Daniela Retamales, director of the Fundación Prótesis 3D; and Matías Hurtado, an industrial designer—recognized that this workflow could be digitized entirely. A 3D scanner captures the child's skull geometry in minutes without contact. Custom software models the orthosis to account for projected growth. A 3D printer produces the device in biocompatible, breathable material. Follow-up adjustments are guided by data, not guesswork. The result is not just faster treatment but a process that can be distributed. A local clinic in a regional city can perform the scan and send the data to a central fabrication hub, or train local technicians to handle printing on-site. The clinical expertise becomes less dependent on physical proximity to a specialist.

This compression of time—from eight months to three, a 60 percent reduction—matters more than the headline suggests. A child's skull grows rapidly in the first two years of life. Faster intervention means treatment concludes while the skull is still most responsive to reshaping. It also means families spend less time managing a medical condition, fewer appointments, less disruption. For a parent juggling work and other children, the difference between eight months and three is the difference between manageable and overwhelming.

Casku is not alone in using 3D technology for cranial orthoses. Spanish companies like Talee and Orthomedical 3D operate similar workflows in a more mature market. But Casku's distinction lies in its explicit focus on territorial decentralization. The startup operates across five Chilean cities, deliberately building a network of regional partners rather than concentrating services in Santiago. This is a deliberate choice about what problem to solve first: not cost, not technological sophistication, but access.

The regulatory path ahead is substantial. Cranial orthoses are classified as medical devices, which means ISO 13485 quality management certification, biocompatibility testing for prolonged skin contact with infants, clinical evidence of safety and efficacy, and registration with national health authorities. In Chile, that means the Ministry of Health. In Europe, the Medical Devices Regulation imposes even stricter requirements. The timeline from prototype to commercialization typically spans six to eighteen months, and that assumes no complications. For founders considering entry into this space, underestimating the regulatory burden is a common and costly mistake.

Casku applied to StartUp Chile in April 2025, seeking not just capital but institutional validation. In LATAM's fragmented healthtech landscape, public acceleration programs serve a function beyond funding: they signal credibility to clinical partners and B2B customers. The company's model is fundamentally B2B2C—pediatricians refer patients to Casku, not the reverse. The moat is not the technology itself, which can be replicated, but the network of clinical relationships and the trust those relationships carry.

The market opportunity is real but narrow. Cranial orthoses are high-value, low-volume: not a mass-market product but a specialized intervention for a defined population. This shapes everything about how the business must operate. Customer lifetime value matters far more than customer acquisition cost. A pediatric clinic that refers dozens of cases annually is worth more than a thousand individual parents reached through advertising. The question for Casku and any competitor is not whether 3D printing works—it clearly does—but whether a distributed network of regional partners can be built and maintained at scale. That is a question about operations, trust, and sustained clinical relationships. It is a question about whether technology can truly overcome geography, or whether geography will always find a way to reassert itself.